CTOs on the Move

emtelligent

www.emtelligent.com

 
Our emtelliPro NLP engine transforms difficult-to-use, narrative medical text into valuable and actionable insights. Enable innovation. Improve competitiveness. Drive performance.
  • Number of Employees: 0-25
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Similar Companies

NEW Health Programs Association

NEW Health provides high quality health care services for all residents within the communities we serve. We offer a sliding fee discount for health services to those who qualify.   We believe that all people deserve...

Aton Pharma

Aton Pharma is a Madison, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Accord Healthcare

Accord Healthcare is a global provider of generic and specialty pharmaceuticals. Our focus on a rapidly expanding portfolio of affordable generic…

Tanner Pharma

For over 18 years, Tanner Pharma Group has provided highly specialized pharmaceutical services to its partners around the world. Leading pharmaceutical and biotech companies partner with Tanner Pharma to license and commercialize their products in challenging international markets, develop and manage their Global Access Programmes, and source comparator drugs for clinical trials and bioanalysis. By partnering with Tanner Pharma, manufacturers are able to focus on their primary markets and strategies while ensuring that the services they need will follow a strictly controlled protocol of quality. Headquartered in the U.S. with offices in London, São Paulo and Mexico City, Tanner Pharma Group`s reach includes Europe, Asia, the Middle East, Australia, Canada and Latin America. We measure our value as a company based on the lives we help to improve. For all of us involved in the pharmaceutical supply chain - manufacturers, distributors, pharmacists, doctors, and others - it is ultimately the patient that matters most. Therefore, we start each day with a renewed commitment to ethically supply unlicensed medicines to markets where access continues being a challenge.